Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
04/2014
04/01/2014US8685437 Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
04/01/2014US8685436 Use of hydroxyflavanones for masking bitter taste
04/01/2014US8685383 Protein-polymer-drug conjugates
04/01/2014CA2687141C Compositions and methods for producing bioactive fusion proteins
04/01/2014CA2661995C Antigenic protein conjugates and process for preparing same
04/01/2014CA2524184C Microbial cellulose wound dressing comprising phmb
04/01/2014CA2510196C Intracutaneous injection
04/01/2014CA2493928C Nucleic acids and corresponding proteins entitled 273p4b7 useful in treatment and detection of cancer
04/01/2014CA2488677C Method of inhibiting prostate cancer cell proliferation
04/01/2014CA2413354C Neurotoxic a.beta. oligomers in alzheimer's disease
03/2014
03/28/2014CA2828588A1 Patch preparation containing amine oxide
03/28/2014CA2791206A1 Abuse deterrent pharmaceutical formulation
03/27/2014WO2014047324A1 Fiber spheres
03/27/2014WO2014047318A1 Delivery of therapeutic compounds with iron oxide nanoparticles
03/27/2014WO2014047199A1 Novel prodrugs for selective anticancer therapy
03/27/2014WO2014047007A1 Suspension pharmaceutical formulations comprising low melting propionic acid derivative particles
03/27/2014WO2014047005A1 Sustained release oral dosage forms comprising low melting propionic acid derivative particles
03/27/2014WO2014046807A1 Hydrophobic shielding for enhanced nanoparticle stability
03/27/2014WO2014046630A1 Tumor targeted liposomal drug delivery system
03/27/2014WO2014046490A1 Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
03/27/2014WO2014046481A1 Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
03/27/2014WO2014046478A1 Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
03/27/2014WO2014046423A1 Peptide having cancer selective translocation function and use thereof
03/27/2014WO2014046415A1 Method for preparing in situ-formed hydrogel using enzyme-immobilized support, and biomedical use thereof
03/27/2014WO2014046312A1 Oral preparation and method for producing the same
03/27/2014WO2014046243A1 Support body for transdermal patch or transdermal preparation, and transdermal patch and transdermal preparation using same
03/27/2014WO2014046191A1 Local-anesthetic long-lasting sustained-release liposome preparation
03/27/2014WO2014046129A1 Pharmaceutical composition for oral administration with improved elution and/or absorbency
03/27/2014WO2014046065A1 Advanced heart failure treatment material as myocardial/cardiovascular regeneration device
03/27/2014WO2014046035A1 Disintegrating particle composition containing acid-type carboxymethylcellulose and crystalline cellulose, and orally disintegrating tablet containing said composition
03/27/2014WO2014045534A1 Adsorption method, adsorption/separation method, and carrier for drug delivery
03/27/2014WO2014045022A2 Agents and methods
03/27/2014WO2014044896A1 Orodispersible pharmaceutical composition of melatonin
03/27/2014WO2014044342A1 Magnesium hydroxide carbonate as carrier material in active ingredient-containing preparations
03/27/2014WO2014043743A1 Viscous haemostatic compostions and method of treatment
03/27/2014WO2014022501A3 Strain-promoted crosslinking of peg-based hydrogels via copper-free cycloaddition
03/27/2014WO2014020130A3 Albumin composition
03/27/2014WO2014016848A3 Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
03/27/2014WO2013184036A3 Hepatoprotective agent
03/27/2014WO2013130669A8 Pharmaceutical composition and administration thereof
03/27/2014WO2013036383A8 Oral delivery for hemoglobin based oxygen carriers
03/27/2014US20140088298 Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
03/27/2014US20140088200 Composition to Enhance the Bioavailability of Curcumin
03/27/2014US20140088166 Process of making and using pharmaceutical formulations of antineoplastic agents
03/27/2014US20140088135 Immunosuppressive macrolide powder for oral suspension
03/27/2014US20140088131 Implantable Polymeric Device for Sustained Release of Buprenorphine
03/27/2014US20140088107 Ophthalmic preparation comprising a pgf2alpha analogue
03/27/2014US20140088089 Cytotoxic benzodiazepine derivatives and methods of preparation
03/27/2014US20140088062 Compositions comprising fusidic acid and packages therefor
03/27/2014US20140088059 Compositions and Methods for Localized Drug Delivery through Mammary Papillae
03/27/2014US20140088039 Ophthalmic solution containing hyaluronic acid or salt thereof and propylene glycol
03/27/2014US20140088038 Compositions and methods for stabilized polysaccharide formulations
03/27/2014US20140088021 Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
03/27/2014US20140088013 Complexation of Metal Ions with Polypeptides
03/27/2014US20140088010 Pharmaceutical preparation
03/27/2014US20140088003 Polymer-based sustained release device
03/27/2014US20140087991 Peptide prodrugs
03/27/2014US20140087060 Process For Producing A Solid Dispersion Of An Active Ingredient
03/27/2014US20140086996 Water-soluble drug carrier and process for producing the same
03/27/2014US20140086993 Storage-Stable Dust-Free Homogeneous Particulate Formulation Comprising At Least One Water-Soluble Vitamin E-Derivative And At Least One Hydrophilic Polymer
03/27/2014US20140086991 Controlled Agglomeration
03/27/2014US20140086988 Stabilized Protein Crystals, Formulations Containing Them and Methods of Making Them
03/27/2014US20140086976 Compositions containing protein polymers and vaccinia virus, and methods of use thereof
03/27/2014US20140086975 Hydrogel formulation for dermal and ocular delivery
03/27/2014US20140086973 Pharmaceutical preparation
03/27/2014US20140086972 Microfabricated nanopore device for sustained release of therapeutic agent
03/27/2014US20140086942 Variant Target Binding Agents and Uses Thereof
03/27/2014US20140086941 SUBSTITUTED 2-BENZYLIDENE-2H-BENZO[b][1,4]THIAZIN-3(4H)-ONES, DERIVATIVES THEREOF, AND THERAPEUTIC USES THEREOF
03/27/2014US20140086940 Herceptin® adjuvant therapy
03/27/2014US20140086932 Method for enhancing specific immunotherapies in cancer treatment
03/27/2014US20140086931 Formulation of human antibodies for treating tnf-alpha associated disorders
03/27/2014US20140086930 Formulation of human antibodies for treating tnf-alpha associated disorders
03/27/2014US20140086929 Formulation of human antibodies for treating tnf-alpha associated disorders
03/27/2014US20140086918 Methods for Inhibiting Prostate Cancer
03/27/2014US20140086900 Lyophilized Preparation of Botulinum Toxin
03/27/2014US20140086857 Compositions Comprising Siloxane Polymer
03/27/2014US20140086854 Polymers Based On Sulfonic Acids, Amides And Special Cross-Linking Agents
03/27/2014US20140086847 Dosage form that is safeguarded from abuse
03/27/2014US20140086843 Bifunctional hydroxy-bisphosphonic acid derivatives
03/27/2014US20140086831 Single Wall Nanotube Constructs and Uses Thereof
03/27/2014US20140086828 Modified gold nanoparticles for therapy
03/26/2014EP2711376A1 Fgfr-fc fusion protein and use thereof
03/26/2014EP2711025A2 Self-assembling peptides incorporating modifications and methods of use thereof
03/26/2014EP2711024A1 Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
03/26/2014EP2711018A1 Engineered Fc regions for site-specific conjugation
03/26/2014EP2711011A1 Panaxadiol-containing composition
03/26/2014EP2711010A1 Pharmaceutical composition
03/26/2014EP2711005A1 Compound dual-release capsule formulation comprised of bromodihydroarteisinin and fe2+ agent
03/26/2014EP2711001A2 Organogel compositions and processes for producing
03/26/2014EP2710999A1 Stable ophthalmic formulations
03/26/2014EP2710129A1 Therapeutic fusion proteins
03/26/2014EP2710034A1 Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms
03/26/2014EP2710031A2 Improved peptide pharmaceuticals for insulin resistance
03/26/2014EP2710025A1 Method for separating a mixture of a protein and the reaction product thereof with a polyalkylene glycol
03/26/2014EP2709670A2 Targeted delivery of proteins across the blood brain barrier
03/26/2014EP2709669A1 Methods for maintaining pegylation of polypeptides
03/26/2014EP2709668A1 Bio-orthogonal drug activation
03/26/2014EP2709667A1 Bio-orthogonal drug activation
03/26/2014EP2709666A1 Bio-orthogonal drug activation
03/26/2014EP2709665A1 Treatment of psoriasis
1 ... 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 ... 1712